|
Balance Sheet Cash Flow Statement 170 Harbor Way South San Francisco, CA 94083 CA Tel. 650-837-7000 Fax 650-837-8300 |
Type: Public
On the web:
http://www.exelixis.com
Employees:
676
Employee growth: (8.0%)
We've come a long way, baby, but we still have a lot in common with the fruit fly. Exelixis, a pharmaceutical research and development firm, got its start analyzing genetic data from fruit flies and other organisms as a means to speed the development of drugs and other products. Its early genomic work has yielded a pipeline of drug candidates primarily in the area of cancer therapies, as well as some potential treatments for metabolic and cardiovascular diseases. The company's drug candidates in clinical trials include treatments for solid tumors, thyroid cancer, and non-small cell lung cancer. Development and licensing partners include Bristol-Myers Squibb, Genentech, GlaxoSmithKline, and Sanofi-Aventis.
Key numbers for fiscal year ending December, 2008:
Sales: $117.9M
One year growth: 3.9%
Net income: ($162.9)M
Officers:
Chairman: Stelios Papadopoulos
President, CEO, and Director: George A. Scangos
SVP Operations: Lupe M. Rivera
Competitors:
AstraZeneca
Genentech
OSI Pharmaceuticals
